Reply Shapes the Future of Autonomous Mobile Robots with the Power of Microsoft Azure
6.7.2021 10:30:00 EEST | Business Wire | Press release
Reply announced today that it has developed an end-to-end solution architecture for autonomous mobile robots (AMR) on Microsoft Azure that enables new business applications across industries, reduces upfront costs and allows for the rapid implementation of customer-specific robotics use cases.
The solution combines Microsoft Azure services, the agility of Boston Dynamics' SPOT and Reply’s knowledge of intelligent cloud computing services, edge computing and artificial intelligence. To demonstrate the capabilities of a scalable and versatile robotics platform, Reply implemented an automated vehicle-damage-detection solution for rental or leasing companies that leverages this architecture. In fact, rental or leasing companies must inspect vehicles for any damage after they are returned in order to ensure the safety and quality of their fleet for their customers. This is usually done in the time- and cost-consuming manual process of walking around the car, visually inspecting it, assessing the severity of the damage and conducting a damage report.
Reply integrates Azure Cognitive Services, Machine Learning and DevOps as well as Power Apps and Power BI. Thanks to Azure's intelligent service foundation, agile workflows and machine learning, this process can be fully automated. Using computer vision, SPOT moves freely through the parking area and scans the license plates to find the right vehicle. Once detected, it walks around the vehicle to record its condition by continuously collecting visual data with its camera and sensors. This information is processed “on the edge” or transmitted to the cloud, where advanced image recognition and machine leaning algorithms perform the damage detection. All detected damages are saved in the return protocol, and they can be presented to the customer and the fleet manager for approval.
“This platform sets the power of Microsoft Azure on the move by bringing it from the Cloud to the Edge and into highly advanced mobile robotic devices, giving them the autonomy to unlock novel business use cases. Thanks to the agile reference architecture, we are able to implement customer-specific use cases in various industries that include all types of mobile robots or drones”, comments Filippo Rizzante, CTO Reply.
“Reply is a long-term, trusted partner in delivering Azure IoT solutions, and we’re delighted to continue our collaboration on this new scalable robotics offering. By leveraging Microsoft Azure, we can help accelerate this transformation by making it easier for businesses to bring AI and analytics capabilities to these autonomous systems in a consistent and secure way,” adds Lakecia Gunter, Vice President and GM, Global IOT Channel at Microsoft.
With their agility, autonomous mobile robots (AMR) are able to move independently from a central infrastructure on terrain that is not traditionally designed for robots. They can be used in hazardous environments and environments, that are harmful to people. According to ResearchAndMarkets.com, the global market for automated guided vehicle (AGV) and AMR is expected to reach $13.2 Billion by 2026 with a growth rate of around 35%. Both AGVs and AMRs collectively are going to cross the installed base of 1.5 Million in the next 5 years to make mobile robots a new normal in our day-to-day operational activities.
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
Source Global Mobile Robots (AGV & AMR) Market:
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005133/en/
Contact information
Media
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594
Sandra Dennhardt
s.dennhardt@reply.com
+49 170 454 62 29
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 18:08:00 EEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubrutinib) plus next-generation BCL2 inhibitor BEQALZI™ (sonrotoclax; ZS), which continue to demonstrate rapid, deep, durable responses across multiple B-cell malignancies. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “BTK inhibition has reshaped the treatment of B-cell cancers, and we believe degradation is the next leap forwa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom